- Home
- ADPT vs DAWN Comparison
ADPT vs DAWN Comparison
Compare ADPT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADPT | DAWN |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ADPT | DAWN |
|---|---|---|
| Price | $12.44 | $21.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $17.78 | ★ $26.00 |
| AVG Volume (30 Days) | 1.5M | ★ 5.4M |
| Earning Date | 05-05-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $276,976,000.00 | $158,182,000.00 |
| Revenue This Year | $3.98 | $53.52 |
| Revenue Next Year | $22.72 | $27.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | 20.60 |
| 52 Week Low | $6.68 | $5.64 |
| 52 Week High | $20.76 | $21.40 |
Technical Indicators
Market Signals| Indicator | ADPT | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 82.06 |
| Support Level | $12.32 | $6.45 |
| Resistance Level | $13.45 | N/A |
| Average True Range (ATR) | 0.83 | 0.60 |
| MACD | -0.26 | 1.13 |
| Stochastic Oscillator | 10.61 | 99.04 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.